SPRAY ADMINISTRATION OF COMPOSITIONS INCLUDING ACTIVE AGENTS SUCH AS PEPTIDES TO THE GASTROINTESTINAL TRACT

• US 20100145301A1
• Filed: 02/07/2008
• Published: 06/10/2010
• Est. Priority Date: 02/26/2007
• Status: Abandoned Application

• Current Assignee: Duocure, Inc.
• Original Assignee: Duocure, Inc.
• Inventors: Magal, Elad
• Application Number:
  US12/522,267
• Publication Number:
  US 20100145301A1
• Time in Patent Office: Days
• US Class Current: 604/503
• CPC Class Codes: A61F 5/0003 Apparatus for the treatment of obesity; Anti-eating devices surgical instruments or methods for treatment of obesity, devices specially adapted therefor A61B17/00; hollow or tubular parts of organs A61F2/04
• CPC Class Codes: A61F 5/0036 Intragastrical devices
• CPC Class Codes: A61K 9/0065 Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
• CPC Class Codes: A61M 2005/1726 the body parameters being measured at, or proximate to, the infusion site
• CPC Class Codes: A61M 2210/1053 Stomach
• CPC Class Codes: A61M 2210/1057 Duodenum
• CPC Class Codes: A61M 2210/106 Small intestine
• CPC Class Codes: A61M 2230/04 Heartbeat characteristics, e.g. ECG, blood pressure modulation
• CPC Class Codes: A61M 2230/08 Other bio-electrical signals
• CPC Class Codes: A61M 2230/60 Muscle strain, i.e. measured on the user
• CPC Class Codes: A61M 5/14276 specially adapted for implantation

Abstract

Methods of administering an active agent such as an active pharmaceutical ingredient by spraying a composition comprising the active agent at a luminal wall of the gastrointestinal tract are disclosed. Also disclosed are devices for administering a composition suitable for implementing the disclosed method. Also disclosed is the use of a peptide as an active agent for the manufacture of a sprayable composition for use in the treatment of a subject by gastrointestinal administration.

Claims

1. A device for administering a sprayable composition including an active agent to a luminal wall of the gastrointestinal tract of a subject, comprising:

a) a sprayer configured for deployment in a gastrointestinal tract;

b) a pressure generator configured to dispense a dose of sprayable composition out through said sprayer as a spray upon actuation; and

c) an actuator for actuating said pressure generator upon being triggered.

2. The device of claim 1, configured so that said sprayer is deployable at a specific location in a gastrointestinal tract.

3. The device of claim 1, further comprising:

d) a composition reservoir functionally associated with said pressure generator so that said pressure generator is configured to force sprayable composition from said reservoir out through said sprayer as a spray upon said actuation.

36. The device of claim 3, further comprising a composition including a satiety factor or an analogue thereof or a derivative thereof and a pharmaceutically acceptable carrier held in said reservoir.

37. The device of claim 36, wherein said satiety factor is CCK or an analogue thereof or a derivative thereof.

38. The device of claim 3, further comprising a composition including a peptide active agent and a pharmaceutically acceptable carrier held in said reservoir.

39. The device of claim 38, wherein said active agent is a peptide hormone, an analogue thereof or a derivative thereof.

40. The device of claim 39, wherein said active agent is CCK-8.

41. The device of claim 1, further comprising:

e) an anchor, configured to anchor said sprayer at a specific location in the gastrointestinal tract.

42. The device of claim 1, further comprising:

f) an event detector functionally associated with said actuator, configured so that as a result of detection of an event of significance for administration of an active agent, said event detector triggers said actuator.

43. The device of claim 42, wherein said event is a physiological change.

44. The device of claim 1, wherein said sprayer is configured for deployment in the duodenum

45. The device of claim 44, further comprising:

b) a feeder tube including a proximal end functionally associated with said sprayer and a distal end, configured to define a conduit for a sprayable composition from said distal end to said sprayer; and

c) an anchor functionally associated with said distal end of said feeder tube wherein said anchor and said feeder tube are configured so that when properly deployed in the body of a subject, said feeder tube passes through the pyloric sphincter of said subject to maintain said sprayer in the duodenum of a subject.

46. The device of claim 45, further comprising an increased-diameter feature near said distal end of said feeder tube, configured to assist in preventing said sprayer from passing through a pyloric sphincter into the stomach of a subject when properly deployed.

47. The device of claim 45, wherein said feeder tube and said anchoring component are configured so that when properly deployed in the body of a subject, said feeder tube passes through the pyloric sphincter of said subject to maintain said sprayer in the superior portion of the duodenum of a subject.

48. A method of administering an active agent, comprising:

a) deploying a sprayer of a device of claim 1 in a specific location of a gastrointestinal tract of a subject suffering from a condition;

b) providing a sprayable composition comprising an active agent and a pharmaceutically acceptable carrier, said active agent effective in treating said condition; and

c) when necessary, spraying a dose of said sprayable composition through said sprayer against a portion of a luminal wall of said gastrointestinal tract of said subject

thereby administering said active agent so as to treat said condition.

49. The method of claim 48 wherein said necessity of said administering said dose of said active agent is determined by detection of an event of significance for administration of said active agent.

50. The method of claim 49, wherein said event comprises an event selected from the group consisting of gastrointestinal tract activity, food ingestion and hunger, anginal attack, arrhythmia, an asthma attack and an allergic reaction.

51. The method of claim 48, wherein said portion of a luminal wall is a portion of the luminal wall of the duodenum of said subject.

52. The method of claim 48, wherein said active agent is a satiety factor or an analogue thereof or a derivative thereof.

53. The method of claim 52, wherein said satiety factor is CCK or an analogue thereof or a derivative thereof.

54. The method of claim 48, wherein said active agent is a peptide active agent.

55. The method of claim 48, wherein said active agent is a peptide hormone, an analogue thereof or a derivative thereof.

56. The method of claim 55, wherein said active agent is CCK-8.

4-35. -35. (canceled)